Not Signed In -
Meloxicam |
Mobic |
Clinical Trial: Mobicox
This study is currently recruiting patients.
Verified by University Health Network, Toronto September 2005
|
Purpose
Swelling of the prostate can occur during and after a brachytherapy. This swelling can cause urinary problems ranging from difficulty voiding to urinary retention.The purpose of this study is to investigate whether Mobicox started one week before brachytherapy and then continued afterwards is more effective in reducing the risk of needing a catheter than Mobicox given only afterwards.
| Condition | Intervention | Phase |
|---|---|---|
| Prostatic Neoplasms | Drug: Meloxicam | Phase III |
MedlinePlus related topics: Prostate Cancer
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Uncontrolled, Single Group Assignment
Official Title: A Comparison of 2 Schedules of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy - A Randomized Phase III Trial
Further Study Details:
Primary Outcomes: To compare 2 schedules of MeloxicamTM given in the peri-operative period to reduce prostate swelling after permanent seed implantation for prostate cancer
Secondary Outcomes: To determine the influence of different timing of MeloxicamTM administration on urinary toxicity and biochemical response after permanent seed implantation for prostate cancer
Expected Total Enrollment: 100
Secondary Outcomes: To determine the influence of different timing of MeloxicamTM administration on urinary toxicity and biochemical response after permanent seed implantation for prostate cancer
Expected Total Enrollment: 100
Study start: February 2004
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Male
Criteria
Inclusion Criteria:
- Eligible to receive prostate brachytherapy as per the Ontario Provincial Guidelines will be eligible for this study (i.e. PSA < 10, Gleason score <7, Stage £T2a)
Exclusion Criteria:
- Patients already taking anti-inflammatory drugs
- Patients with allergic-type reactions, including asthma and urticaria, to aspirin or nonsteroidal anti-inflammatory agents (see product information)
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00152919
Juanita Crook, MD 416-946-2919 juanita.crook@rmp.uhn.on.ca
Canada, Ontario
Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada; Recruiting
Juanita Crook, MD 416-946-2919 juanita.crook@rmp.uhn.on.ca
Study chairs or principal investigators
Juanita Crook, MD, Principal Investigator, Princess Margaret Hospital
More Information
Study ID Numbers: UHN REB 03-0840-C
Last Updated: September 8, 2005
Record first received: September 8, 2005
ClinicalTrials.gov Identifier: NCT00152919
Health Authority: Canada: Ethics Review Committee
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 8, 2005
Record first received: September 8, 2005
ClinicalTrials.gov Identifier: NCT00152919
Health Authority: Canada: Ethics Review Committee
ClinicalTrials.gov processed this record on 2005-09-13
email this page
print this page
bookmark this page
feedback on this page
